Horizon Europe opens new health research funding calls

Feb 3, 2022

Several calls for funding have been recently opened within Horizon Europe, the European funding programme for research and innovation with a budget of €95.5 billion.

The programme aims to facilitate collaboration and strengthen the impact of research and innovation in developing, supporting and implementing EU policies while tackling global challenges. It also supports creating and better dispersing of excellent knowledge and technologies.

We encourage our partners to apply to the 2022 calls especially those under the Cluster 1 – Health of the Pillar 2 – Global Challenges and European Industrial Competitiveness.

  • Destination 1. Staying healthy in a rapidly changing society

This call is focused on personalised approaches for disease prevention that seek to determine the predisposition to disease and deliver timely and targeted prevention measures. Understanding the risk factors that trigger the health-to-disease transition is essential for delivering personalized prevention measures or reducing the burden of chronic diseases.

  • Destination 3. Tackling diseases and reducing disease burden
    • Non-communicable diseases risk reduction in adolescence and youth (Global Alliance for Chronic Diseases – GACD) (HORIZON-HLTH-2022-DISEASE-07-03) – RIA. Deadline: 21 Apr 2022

The topic is focused on implementation research about common risk prevention interventions targeting adolescents and youth to reduce the impact of non-communicable diseases in low- and middle-income countries and vulnerable populations in high-income countries. Proposals should focus on implementation science around evidence-based interventions that promote healthy behaviours, and that have the potential to profoundly reduce the risk of chronic diseases and multimorbidity.

  • Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
    • Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers (HORIZON-HLTH-2022-TOOL-11-01)- RIA. Deadline: 21 Apr 2022

The applicants should perform the clinical validation of qualified biomarkers (not limited to molecular biomarkers) that will enable the identification of appropriate patients to ensure an effective and efficient use of existing pharmaceuticals in the treatment of major diseases and conditions

  • New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment (HORIZON-HLTH-2022-TOOL-11-02) – RIA. Deadline: 21 Apr 2022

To harness the potential of Real-World Data (RWD) and synthetic data from digital twins and advanced analytical models and make them actionable for health regulatory decision-making and for health technology assessment, targeted research is needed on the evidentiary value of these data for a number of relevant use cases

Stay tuned for further updates and spread the word.

Recent posts in News